AAV-IL-10 + AAV-M3
AAV-IL-10 + AAV-M3 has been studied in 1 paper since 2020: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Nov 30, 2020: “IL-10 based immunomodulation initiated at birth extends lifespan in a familial mouse model of amyotrophic lateral sclerosis”.
1 paper studies it1 findingUpdated
- 1 lab in 1 country
- Funders: National Institute of Neurological Disorders and Stroke and 1 more
- Animals1
What did studies of AAV-IL-10 + AAV-M3 find?
1Studies of AAV-IL-10 + AAV-M3 measured 1 outcome; the most studied are age to paralysis (1 study).
Age to paralysis
upin mice1
1 study
Age to paralysis
upin mice1
AAV-IL-10 + AAV-M3 improves age to paralysis in mice.
“expression of an anti-inflammatory cytokine and a decoy chemokine receptor can modulate inflammatory processes in SOD1-G93A mice, modestly delaying the age to paralysis”
Animalsin SOD1-G93A mice
Scientific reports